1-12 of 12
Vania T.M. Hungria, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Philippe Moreau, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Michele Cavo, Javier De La Rubia, Rakesh Popat, Cristina Gasparetto, MD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, Francesca Gay, MD, Gábor Mikala, MD PhD, Elizabeth A Punnoose, PhD, Wan-Jen Hong, MD, Anjla Sood, MD, Muhammad Jalaluddin, PhD, Jeremy A. Ross, PhD, James E. Ward, MD, Paulo C. Maciag, MD PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1888.
https://doi.org/10.1182/blood-2019-126015
Published: 2019
Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Saad Z. Usmani, MD, Maria-Victoria Mateos, MD PhD, Hareth Nahi, MD PhD, Sebastian Grosicki, MD PhD, Vladimir I. Vorobyev, MD PhD, Ivan Spicka, MD PhD Prof, Vania T.M. Hungria, MD PhD, Sibirina Korenkova, Max Flogegard, Joan Bladé, MD PhD, Philippe Moreau, MD, Martin F. Kaiser, Shinsuke Iida, MD PhD, Jacob P. Laubach, MD, Tara Masterson, Kristen Anne Lantz, PhD, Lisa O'Rourke, MSN, RN, Christoph Heuck, Xiang Qin, Dolly A. Parasrampuria, PhD, Ming Qi, Nizar Bahlis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1865.
https://doi.org/10.1182/blood-2019-122765
Published: 2019
Journal Articles

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Roman Hajek, Prof, MD PhD, Jiri Minarik, MD PhD, Jan Straub, MD, Ludek Pour, MD, Alexandra Jungova, Jesus G. Berdeja, MD, Mario Boccadoro, Lucie Brožová, MSc, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Frits van Rhee, MD PhD, Jorge Vela-Ojeda, MD PhD, Michael A. Thompson, MD PhD FASCO, Rafat Abonour, MD, Ajai Chari, MD, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Caitlin L. Costello, MD, Faith E. Davies, MD, Vania T.M. Hungria, MD PhD, Hans C. Lee, MD, Xavier Leleu, MD PhD, Noemi Puig, MD PhD, Robert M. Rifkin, MD, Evangelos Terpos, MD PhD, Saad Z. Usmani, MD FACP, Katja C. Weisel, MD, Jeffrey A. Zonder, Magda Bařinová, MSc, Matyáš Kuhn, MSc, Jiri Silar, MSc, Lenka Capkova, Kenny Galvez, MD, Jin Lu, MDProf, Tomas Skacel, MD, Jennifer Elliott, Brittany Demers, BS, BA, Dawn Marie Stull, Pharm.D., BCOP, Kaili Ren, PhD, Vladimir Maisnar, MD PhD MBA
Journal: Blood
Blood (2019) 134 (Supplement_1): 1845.
https://doi.org/10.1182/blood-2019-126606
Published: 2019
Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

Maria-Victoria Mateos, MD PhD, Saad Z. Usmani, MD, Sebastian Grosicki, MD PhD, Vladimir I. Vorobyev, MD PhD, Ivan Spicka, MD PhD Prof, Vania T.M. Hungria, MD PhD, Sibirina Korenkova, Nizar Bahlis, MD, Max Flogegard, Joan Bladé, MD PhD, Philippe Moreau, MD, Martin F. Kaiser, Shinsuke Iida, MD PhD, Jacob P. Laubach, MD, Tara Masterson, Kristen Anne Lantz, PhD, Lisa O'Rourke, MSN, RN, Xiang Qin, Dolly A. Parasrampuria, PhD, Christoph Heuck, Ming Qi, MD PhD, Hareth Nahi, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1906.
https://doi.org/10.1182/blood-2019-122501
Published: 2019
Journal Articles

Comparison of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) with Standard of Care for Patients from Latin America with Newly Diagnosed Multiple Myeloma (NDMM) Who Were Transplant Ineligible: A Propensity Score Matching Analysis

Vania T.M. Hungria, MD PhD, Deborah M. Martinez-Banos, Maria-Victoria Mateos, Meletios A. Dimopoulos, MD, Michele Cavo, Bart Heeg, PhD, Annette Lam, Gerardo Machnicki, Jianming He, PhD, Mariana Fernandez
Journal: Blood
Blood (2019) 134 (Supplement_1): 2143.
https://doi.org/10.1182/blood-2019-123557
Published: 2019
Journal Articles

T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study

Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Michele Cavo, Javier De La Rubia, Rakesh Popat, Cristina Gasparetto, MD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, Philippe Moreau, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Michael E O'Dwyer, MD, Mamta Garg, MD FRCP, FRCPath, Elizabeth A Punnoose, PhD, Muhammad Jalaluddin, PhD, Jia Jia, PhD MBA, Xiaoqing Yang, PhD, Yan Sun, PhD, James E. Ward, MD, Paulo C. Maciag, MD PhD, Jeremy A. Ross, PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 142.
https://doi.org/10.1182/blood-2019-126094
Published: 2019
Journal Articles

Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone

Cristina Gasparetto, MD, Rakesh Popat, Shaji K. Kumar, MD, Michele Cavo, Javier de la Rubia, MD PhD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, James Maciel, Liang-Tsai Hsiao, Philippe Moreau, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Jia Jia, PhD MBA, Sudeep Karve, PhD, Esprit Ma, Jacob Devine, MA, Katy Benjamin
Journal: Blood
Blood (2019) 134 (Supplement_1): 3177.
https://doi.org/10.1182/blood-2019-127387
Published: 2019
Journal Articles

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update

Ajai Chari, MD, Jesús San-Miguel, Helen McCarthy, MBBS, PhD, Kenshi Suzuki, MD PhD, Vania T.M. Hungria, MD PhD, Anna Sureda, MD PhD, Aurore Perrot, MD PhD, Cyrille Hulin, MD, Hila Magen, MD, Shinsuke Iida, MD PhD, Vladimir Maisnar, MD PhD MBA, Lionel Karlin, MD, Ludek Pour, MD, Dolly A. Parasrampuria, PhD, Tara Masterson, Michele Kosh, RN, BSN, Shiyi Yang, Maria L. Delioukina, MD, Ming Qi, MD PhD, Robin Carson, MD BA, Cyrille Touzeau, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3152.
https://doi.org/10.1182/blood-2019-123560
Published: 2019
Journal Articles

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor

Katja C. Weisel, MD, Pieter Sonneveld, Maria-Victoria Mateos, Vania T.M. Hungria, MD PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Jane Estell, FRACP, Wolney G Barreto, Paolo Corradini, Chang-Ki Min, MD PhD, Eva Medvedova, MD, Maria Krevvata, PhD, Sonali Trivedi, Xiang Qin, Huiling Pei, PhD, Jon Ukropec, PhD, Rachel Kobos, MD, Ming Qi, MD PhD, Ajay K Nooka, MDMPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 3192.
https://doi.org/10.1182/blood-2019-123527
Published: 2019
Journal Articles

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study

Vania T.M. Hungria, MD PhD, Hans C. Lee, MD, Rafat Abonour, MD, Robert M. Rifkin, MD, Evangelos Terpos, MD PhD, Xavier Leleu, MD PhD, Caitlin L. Costello, MD, Frits van Rhee, MD PhD, Katja C. Weisel, MD, Noemi Puig, MD PhD, Jesus G. Berdeja, MD, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Saad Z. Usmani, MD FACP, Michael A. Thompson, MD PhD FASCO, Mario Boccadoro, Jeffrey A. Zonder, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Roman Hajek, Prof, MD PhD, Suzanne R. Fanning, DO, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Jim Omel, MD, Mira Armour, BSc, Kathryn E. Morgan, Ronak S. Patel, Gary L. Carlson, Renda H. Ferrari, PhD, Dawn Marie Stull, Pharm.D., BCOP, Kaili Ren, PhD, Dasha Cherepanov, PhD, James V. Pottala, PhD, Ajai Chari, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1887.
https://doi.org/10.1182/blood-2019-125749
Published: 2019
Journal Articles

Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Jesús F. San-Miguel, MD, Vania T.M. Hungria, MD PhD, Sung-Soo Yoon, MDPhD, Meral Beksac, MD, Meletios A. Dimopoulos, Ashraf Elghandour, MD, Wieslaw W. Jedrzejczak, MD, Andreas Guenther, MD, Thanyaphong Na Nakorn, MD, Noppadol Siritanaratkul, Robert L. Schlossman, MD, Jian Hou, MD PhD, Philippe Moreau, Sagar Lonial, MD, Jae Hoon Lee, MD, Hermann Einsele, MD, Monika Sopala, PhD, Bourras-Rezki Bengoudifa, MS, Claudia Corrado, MD, Paul G. Richardson
Journal: Blood
Blood (2015) 126 (23): 3026.
https://doi.org/10.1182/blood.V126.23.3026.3026
Published: 2015
Journal Articles

Nasal/Nasal Type NK/T-Cell Lymphoma: A Brazilian Experience of 40 Cases.

Carlos Chiattone, MD, PhD, Roberto P. Paes, MD,PhD, Lidio Granato, MD,PhD, Vania T.M. Hungria, MD,PhD, Fausto F. Alonso, MD,PhD, Peter G. Isaacson, MBChB,DM,FRCPath
Journal: Blood
Blood (2006) 108 (11): 4627.
https://doi.org/10.1182/blood.V108.11.4627.4627
Published: 2006